{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052121","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.659423+00:00","generated_at":"2026-06-03T00:53:09.627962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biomea Fusion Q1 2024 net loss $39.1M; cash $145.3M; positive diabetes clinical data","bullets":["Net loss of $39.1M in Q1 2024 (incl. $5.0M stock comp) vs $29.1M in Q1 2023; R&D expenses rose to $33.8M.","Cash, equivalents and restricted cash $145.3M at March 31, 2024, down from $177.2M at Dec 31, 2023.","In type 2 diabetes COVALENT-111, 20%/36% of 100mg/200mg cohorts achieved durable HbA1c ≥1.0% reduction off therapy at 26 weeks.","In type 1 diabetes COVALENT-112, first two patients showed improved beta-cell function (C-peptide Index) after BMF-219; well tolerated.","Plan to report Week 26 data from >200 T2D patients (~40 T1D patients) in 2024; expect lower opex in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052121","json":"https://secwatch.observer/filing/0000950170-24-052121.json","markdown":"https://secwatch.observer/filing/0000950170-24-052121.md","text":"https://secwatch.observer/filing/0000950170-24-052121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/0000950170-24-052121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/bmea-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:53:09.627962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fda0c293df9e4a72725a03a2355e7e5b2fe6a3d3","claim":"Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/0000950170-24-052121-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}